Nal-IRI/FL
Phase 1Small molecule
Nal-IRI/FL is one of 82 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1MS Contin
Merck & Co.Preclinical
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
ABI-007
Bristol-Myers SquibbPreclinical
Thiazolidinediones
SanofiPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Meglitinides
SanofiPreclinical
Chemotherapy Agents
TakedaPreclinical
Active Comparator
ModernaPreclinical
LDE225
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nal-IRI/FL. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSONIRE Therapeutics Inc.